Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of coronary artery disease on clinical outcomes after TAVR: Insights from the BRAVO-3 randomized trial.
Feldman D, Cao D, Sartori S, Zhang Z, Hengstenberg C, Tron C, Anthopoulos P, Widder JD, Meneveau N, Stella PR, Ferrari M, Jeger R, Violini R, Dumonteil N, Chen S, Yan R, Nicolas J, Razuk V, Spirito A, Vogel B, Mehran R, Dangas G. Feldman D, et al. Among authors: anthopoulos p. Catheter Cardiovasc Interv. 2023 May;101(6):1134-1143. doi: 10.1002/ccd.30647. Epub 2023 Apr 10. Catheter Cardiovasc Interv. 2023. PMID: 37036268 Clinical Trial.
Sex-based differences in outcomes with bivalirudin or unfractionated heparin for transcatheter aortic valve replacement: Results from the BRAVO-3 randomized trial.
Asgar A, Chandrasekhar J, Mikhail G, Webb J, Lefèvre T, Tamburino C, Hildick-Smith D, Hambrecht R, Van Belle E, Widder J, Dumonteil N, Hink U, Jeger R, Linke A, Deliargyris E, Gao P, Mehran R, Hengstenberg C, Anthopoulos P, Dangas G; BRAVO-3 Investigators. Asgar A, et al. Among authors: anthopoulos p. Catheter Cardiovasc Interv. 2017 Jan;89(1):144-153. doi: 10.1002/ccd.26607. Epub 2016 Aug 16. Catheter Cardiovasc Interv. 2017. PMID: 27152677
Impact of pre-existing or new-onset atrial fibrillation on 30-day clinical outcomes following transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial.
Hengstenberg C, Chandrasekhar J, Sartori S, Lefevre T, Mikhail G, Meneveau N, Tron C, Jeger R, Kupatt C, Vogel B, Farhan S, Sorrentino S, Sharma M, Snyder C, Husser O, Boekstegers P, Hambrecht R, Widder J, Hildick-Smith D, De Carlo M, Wijngaard P, Deliargyris E, Bernstein D, Baber U, Mehran R, Anthopoulos P, Dangas G; BRAVO-3 Investigators. Hengstenberg C, et al. Among authors: anthopoulos p. Catheter Cardiovasc Interv. 2017 Nov 15;90(6):1027-1037. doi: 10.1002/ccd.27155. Epub 2017 Jun 20. Catheter Cardiovasc Interv. 2017. PMID: 28493641 Clinical Trial.
Effect of valve design and anticoagulation strategy on 30-day clinical outcomes in transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial.
Linke A, Chandrasekhar J, Sartori S, Lefevre T, van Belle E, Schaefer U, Tchetche D, Sardella G, Webb J, Colombo A, Windecker S, Vogel B, Farhan S, Sorrentino S, Sharma M, Snyder C, Asgar A, Dumonteil N, Tamburino C, Hink U, Violini R, Stella P, Bernstein D, Deliargyris E, Hengstenberg C, Baber U, Mehran R, Anthopoulos P, Dangas G; BRAVO-3 Investigators. Linke A, et al. Among authors: anthopoulos p. Catheter Cardiovasc Interv. 2017 Nov 15;90(6):1016-1026. doi: 10.1002/ccd.27154. Epub 2017 Jul 19. Catheter Cardiovasc Interv. 2017. PMID: 28498562 Clinical Trial.
Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: A post hoc analysis from the BRAVO-3 randomized trial.
Power D, Schäfer U, Guedeney P, Claessen BE, Sartori S, Sorrentino S, Lefèvre T, Kupatt C, Tchetche D, Dumonteil N, Webb JG, Colombo A, Windecker S, Ten Berg JM, Hildick-Smith D, Boekstegers P, Linke A, Tron C, Van Belle E, Asgar AW, Jeger R, Sardella G, Hink U, Husser O, Grube E, Lechthaler I, Wijngaard P, Anthopoulos P, Deliargyris EN, Bernstein D, Hengstenberg C, Mehran R, Dangas GD. Power D, et al. Among authors: anthopoulos p. Catheter Cardiovasc Interv. 2019 Jun 1;93(7):1374-1381. doi: 10.1002/ccd.28295. Epub 2019 May 22. Catheter Cardiovasc Interv. 2019. PMID: 31116908
Impact of diabetes mellitus on short term vascular complications after TAVR: Results from the BRAVO-3 randomized trial.
Goel R, Power D, Tchetche D, Chandiramani R, Guedeney P, Claessen BE, Sartori S, Cao D, Meneveau N, Tron C, Dumonteil N, Widder JD, Hengstenberg C, Ferrari M, Violini R, Stella PR, Jeger R, Anthopoulos P, Deliargyris EN, Mehran R, Dangas GD. Goel R, et al. Among authors: anthopoulos p. Int J Cardiol. 2019 Dec 15;297:22-29. doi: 10.1016/j.ijcard.2019.09.063. Epub 2019 Oct 11. Int J Cardiol. 2019. PMID: 31630816 Clinical Trial.
Clinical outcomes after TAVR with heparin or bivalirudin as periprocedural anticoagulation in patients with and without peripheral arterial disease: Results from the BRAVO-3 randomized trial.
Zilberszac R, Chandiramani R, Hengstenberg C, Sartori S, Cao D, Chandrasekhar J, Schafer U, Tchetche D, Violini R, Jeger R, Van Belle E, Boekstegers P, Hambrecht R, Tron C, Dumenteil N, Linke A, Ten Berg JM, Deliargyris EN, Anthopoulos P, Mehran R, Dangas G. Zilberszac R, et al. Among authors: anthopoulos p. Catheter Cardiovasc Interv. 2020 Sep 1;96(3):E377-E386. doi: 10.1002/ccd.28642. Epub 2019 Dec 5. Catheter Cardiovasc Interv. 2020. PMID: 31808295 Free PMC article.
The importance of the Heart Team evaluation before transcatheter aortic valve replacement: Results from the BRAVO-3 trial.
Camaj A, Claessen BE, Mehran R, Yudi MB, Power D, Baber U, Hengstenberg C, Lefevre T, Van Belle E, Giustino G, Guedeney P, Sorrentino S, Kupatt C, Webb JG, Hildick-Smith D, Hink HU, Deliargyris EN, Anthopoulos P, Sharma SK, Kini A, Sartori S, Chandrasekhar J, Dangas GD. Camaj A, et al. Among authors: anthopoulos p. Catheter Cardiovasc Interv. 2020 Dec;96(7):E688-E694. doi: 10.1002/ccd.28717. Epub 2020 Jan 13. Catheter Cardiovasc Interv. 2020. PMID: 31943717
Incidence, predictors, and outcomes associated with acute kidney injury in patients undergoing transcatheter aortic valve replacement: from the BRAVO-3 randomized trial.
Chandrasekhar J, Sartori S, Mehran R, Aquino M, Vogel B, Asgar AW, Webb JG, Tchetche D, Dumonteil N, Colombo A, Windecker S, Claessen BE, Ten Berg JM, Hildick-Smith D, Wijngaard P, Lefèvre T, Deliargyris EN, Hengstenberg C, Anthopoulos P, Dangas GD. Chandrasekhar J, et al. Among authors: anthopoulos p. Clin Res Cardiol. 2021 May;110(5):649-657. doi: 10.1007/s00392-020-01787-7. Epub 2021 Apr 11. Clin Res Cardiol. 2021. PMID: 33839885 Clinical Trial.
Impact of anemia on short-term outcomes after TAVR: A subgroup analysis from the BRAVO-3 randomized trial.
Razuk V, Camaj A, Cao D, Nicolas J, Hengstenberg C, Sartori S, Zhang Z, Power D, Beerkens F, Chiarito M, Meneveau N, Tron C, Dumonteil N, Widder JD, Ferrari M, Violini R, Stella PR, Jeger R, Anthopoulos P, Mehran R, Dangas GD. Razuk V, et al. Among authors: anthopoulos p. Catheter Cardiovasc Interv. 2021 Nov 15;98(6):E870-E880. doi: 10.1002/ccd.29753. Epub 2021 May 12. Catheter Cardiovasc Interv. 2021. PMID: 33909348 Clinical Trial.
35 results